Peptide Inhibitors for Galectin-7 Dimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for galectin-7 dimerization are limited by their high molecular weight, low affinity, lack of selectivity, and inability to target CRD-independent functions, which are crucial for modulating galectin activities in cancer therapy.
Innovation Solution
Development of peptides or peptidomimetics that specifically inhibit human galectin-7 dimerization by targeting specific domains such as residues 13-25, 86-102, 95-108, and 129-135, disrupting dimer formation and apoptosis induction in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If carbohydrate-based inhibitors are used to block galectin binding, then extracellular galectin activity is inhibited, but the inhibitors have high molecular weight, low affinity, and lack selectivity
Solution Approach 1:
The patent extracts the critical dimerization interface regions from the full galectin-7 protein to create smaller peptide inhibitors. Specifically, peptides corresponding to residues 13-25, 86-102, 95-108, and 129-135 are identified as sufficient to block dimerization, eliminating the need for high molecular weight carbohydrate-based inhibitors while maintaining inhibition efficacy.
Solution Approach 2:
The patent changes the molecular weight parameter of the inhibitor by transitioning from high molecular weight carbohydrates to low molecular weight peptides (50 residues or less). This parameter change improves affinity and selectivity while reducing molecular weight, directly resolving the contradiction between inhibition efficacy and inhibitor size.
2Reliability
If carbohydrate-based inhibitors are used to block galectin binding, then extracellular galectin activity is inhibited, but the inhibitors lack selectivity for specific galectins
Solution Approach 1:
The patent applies local quality by targeting specific local regions (dimerization interfaces) rather than the entire galectin protein. The peptides correspond to specific residue ranges (13-25, 86-102, 95-108, 129-135) that are unique to galectin-7 dimerization, providing local specificity that enhances selectivity for galectin-7 over other galectins with different dimerization interfaces.
Solution Approach 2:
The patent segments the galectin-7 protein into specific functional domains, identifying that peptides from residues 13-25, 86-102, 95-108, and 129-135 are sufficient for dimerization inhibition. This segmentation allows creation of smaller, more selective inhibitors that target only the dimerization function without affecting other galectin activities, improving both selectivity and affinity.
3Reliability
If conventional inhibitors are used, then extracellular galectin binding is blocked, but CRD-independent functions are not targeted
Solution Approach 1:
The patent extracts and targets the dimerization interface regions separately from the carbohydrate recognition domain (CRD). By focusing on residues 13-25, 86-102, 95-108, and 129-135 that are involved in dimerization rather than carbohydrate binding, the invention isolates and inhibits CRD-independent functions while leaving CRD-mediated activities unaffected, thereby expanding functional coverage.
Solution Approach 2:
The patent segments galectin functions into CRD-dependent and CRD-independent pathways. The peptide inhibitors specifically target the dimerization interface segment, which operates independently of the CRD. This functional segmentation allows selective inhibition of dimerization-mediated processes (such as apoptosis induction) without interfering with carbohydrate binding functions, achieving broader functional coverage.
Data Source
AI summary
Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for, the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.